IN2014MN02539A - - Google Patents

Info

Publication number
IN2014MN02539A
IN2014MN02539A IN2539MUN2014A IN2014MN02539A IN 2014MN02539 A IN2014MN02539 A IN 2014MN02539A IN 2539MUN2014 A IN2539MUN2014 A IN 2539MUN2014A IN 2014MN02539 A IN2014MN02539 A IN 2014MN02539A
Authority
IN
India
Prior art keywords
features
vivo
favorable
analogues
compounds
Prior art date
Application number
Other languages
English (en)
Inventor
J L Kiappes
Peter Laing
Raymond Dwek
Nicole Zitzmann
Stephanie Pollock
Original Assignee
Unither Virology Llc
Univ Oxford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unither Virology Llc, Univ Oxford filed Critical Unither Virology Llc
Publication of IN2014MN02539A publication Critical patent/IN2014MN02539A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06Aminosugars
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
IN2539MUN2014 2012-06-06 2013-06-05 IN2014MN02539A (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261656265P 2012-06-06 2012-06-06
PCT/US2013/044285 WO2013184780A1 (en) 2012-06-06 2013-06-05 Novel iminosugars and their applications

Publications (1)

Publication Number Publication Date
IN2014MN02539A true IN2014MN02539A (sr) 2015-07-24

Family

ID=49712581

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2539MUN2014 IN2014MN02539A (sr) 2012-06-06 2013-06-05

Country Status (8)

Country Link
US (1) US8921568B2 (sr)
EP (1) EP2858642A4 (sr)
JP (1) JP2015518896A (sr)
KR (1) KR20150035767A (sr)
CN (1) CN104703597A (sr)
CA (1) CA2875975A1 (sr)
IN (1) IN2014MN02539A (sr)
WO (1) WO2013184780A1 (sr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113425720A (zh) * 2020-04-03 2021-09-24 深圳前海诺贝尔奖科学家技术转移转化有限公司 亚胺糖化合物在制备抗SARS-CoV-2病毒的药物中的用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6011902B2 (ja) * 1979-12-27 1985-03-28 日本新薬株式会社 モラノリンの誘導体
DE3007078A1 (de) * 1980-02-26 1981-09-10 Bayer Ag, 5090 Leverkusen Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung
US6177447B1 (en) * 1996-07-15 2001-01-23 Universiteit Van Amsterdam Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
US20030100532A1 (en) 1997-02-14 2003-05-29 Gary S. Jacob Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy for treating hepatitis virus infections
BR9813508A (pt) 1997-12-11 2000-10-03 Univ Oxford Inibição de replicação viral associada com membrana
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
US6689759B1 (en) 1998-02-12 2004-02-10 G. D. Searle & Co. Methods of Treating hepatitis virus infections with N-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds in combination therapy
US6809083B1 (en) 1998-02-12 2004-10-26 Richard A. Mueller Use of N-substituted-1, 5-dideoxy-1, 5-imino-D-glucitol compounds for treating hepatitis virus infections
JP2002536407A (ja) 1999-02-12 2002-10-29 ジー・ディー・サール・アンド・カンパニー 肝炎ウィルス感染の治療のための置換−1,5−ジデオキシ−1,5−イミノ−d−グルシトール化合物の使用
AU1840101A (en) 1999-08-10 2001-03-05 Chancellor, Masters And Scholars Of The University Of Oxford, The Long chain n-alkyl compounds and oxo-derivatives thereof
US7256005B2 (en) 1999-08-10 2007-08-14 The Chancellor, Masters And Scholars Of The University Of Oxford Methods for identifying iminosugar derivatives that inhibit HCV p7 ion channel activity
KR100847678B1 (ko) 2000-02-11 2008-07-23 리서치 디벨럽먼트 파운데이션 토코페롤, 토코트리에놀, 다른 크로만 및 측쇄 유도체, 및이들의 용도
WO2001060366A1 (en) * 2000-02-14 2001-08-23 Pharmacia Corporation Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
CN1694696A (zh) 2002-09-23 2005-11-09 牛津大学校委会 亚氨基糖衍生物在抑制离子通道活性中的应用
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
US8481571B2 (en) * 2004-05-04 2013-07-09 Academia Sinica Anti-coronavirus compounds
KR100611931B1 (ko) * 2004-09-02 2006-08-11 강경태 광학활성 알콕시알콜 화합물, 이로부터 유도되는 광학활성1,3-페닐렌-비스[4-(4-알콕시)페닐이미노메틸]벤조에이트화합물 및 이들의 제조방법
US8361999B2 (en) * 2005-04-04 2013-01-29 Pontificia Universidad Catolica De Chile Methods of treating cholesterol gallstone disease with ezetimibe
US8975280B2 (en) 2006-05-24 2015-03-10 The Chancellor, Masters And Scholars Of The University Of Oxford Deoxynojirimycin and D-arabinitol analogs and methods of using
JP2009545621A (ja) 2006-08-02 2009-12-24 ユナイテッド セラピューティクス コーポレーション ウィルス感染症のリポソーム処置
US20090252785A1 (en) 2008-03-26 2009-10-08 University Of Oxford Endoplasmic reticulum targeting liposomes
WO2010027996A1 (en) * 2008-09-02 2010-03-11 Institute For Hepatitis And Virus Research Novel imino sugar derivatives demonstrate potent antiviral activity and reduced toxicity
CA2753195C (en) 2009-02-23 2015-06-02 United Therapeutics Corporation Iminosugars and methods of treating viral diseases
ES2562635T3 (es) 2009-02-24 2016-03-07 United Therapeutics Corporation Iminoazúcares y métodos de tratamiento de infecciones producidas por arenavirus
KR20120059447A (ko) 2009-03-27 2012-06-08 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 콜레스테롤 수준 저하 리포좀
CN102639133B (zh) 2009-06-12 2015-03-11 联合治疗公司 亚氨基糖和治疗布尼亚病毒性疾病以及披膜病毒性疾病的方法
CN102625801B (zh) 2009-09-04 2015-09-09 联合治疗公司 治疗痘病毒感染的方法
KR101497194B1 (ko) 2009-09-04 2015-02-27 유나이티드 세러퓨틱스 코오포레이션 오르토믹소바이러스 감염의 치료 방법
WO2011028779A1 (en) 2009-09-04 2011-03-10 United Therapeutics Corporation Iminosugars and methods of treating filoviral diseases
JP2013512945A (ja) 2009-12-07 2013-04-18 ザ チャンセラー,マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード 破骨細胞生成および/または破骨細胞活性化の阻害における使用のためのn置換デオキシノジリマイシン化合物

Also Published As

Publication number Publication date
US20130331578A1 (en) 2013-12-12
KR20150035767A (ko) 2015-04-07
EP2858642A1 (en) 2015-04-15
CA2875975A1 (en) 2013-12-12
WO2013184780A1 (en) 2013-12-12
US8921568B2 (en) 2014-12-30
CN104703597A (zh) 2015-06-10
JP2015518896A (ja) 2015-07-06
EP2858642A4 (en) 2015-12-02

Similar Documents

Publication Publication Date Title
EA201591662A1 (ru) Липиды и липидные композиции для доставки активных агентов
MX392812B (es) Lipidos cationicos de trialquilo y metodos de uso de los mismos.
EA201201343A1 (ru) Производные 4-аминопиримидина и их действующее вещество как антагонисты аденозинового рецептора а
CR20130617A (es) Derivados de piridin-2(1h)-ona útiles como medicamentos para el tratamiento de trastornos mieloproliferativos, rechazo de trasplantes, enfermedades mediadas por el sistema inmune y enfermedades inflamatorias
EA201590693A1 (ru) Ингибиторы gdf-8
PH12015501074A1 (en) Triazolopyrazine
FR2986002A1 (fr) Nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
PH12015501385A1 (en) Autotaxin inhibitors
MX341332B (es) Lipidos biodegradables para la administracion de agentes activos.
IN2014DN00277A (sr)
EA201492112A1 (ru) ЗАМЕЩЕННЫЕ 3,4-ДИГИДРО-2H-ПИРИДО[1,2-a]ПИРАЗИН-1,6-ДИОНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ ДЛЯ ЛЕЧЕНИЯ (В ТОМ ЧИСЛЕ) БОЛЕЗНИ АЛЬЦГЕЙМЕРА
TW200736234A (en) Chemical compounds
PH12013500152A1 (en) New aminopyrazoloquinazolines
PL3447061T3 (pl) Farmaceutyczna formulacja zawierająca pochodną fosforoamidynianową 5-fluoro-2'-deoksyurydyny do zastosowania w leczeniu nowotworu
NI201500013A (es) Tratamiento de enfermedades inmuno - relacionadas e inflamatorias.
ME03750B (me) Farmaceutska formulacija koja sadrži inozitol
FR2977486B1 (fr) Compositions cosmetiques sous la forme d'emulsions eau-dans-huile comprenant un derive d'acide jasmonique
IN2014DN01619A (sr)
MX357759B (es) Formulaciones y formas de dosificacion de fosfolipidos oxidados.
ECSP099382A (es) Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i
RU2016109986A (ru) Композиция для подавления раковых заболеваний крови или метастазирования рака, содержащая в качестве активного ингредиента моноацетилдиглицеридное соединение
EP4302825A3 (en) Pharmaceutical compositions for treatment of inappetence
HK1216504A1 (zh) 疾病的治療方法
IN2014MN02539A (sr)
EP2815759A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING THE EXTRACT OF LIRIODENDRON TULIPIFERA AS AN ACTIVE SUBSTANCE